Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 732

1.

Non-enzymatic roles of human RAD51 at stalled replication forks.

Mason JM, Chan YL, Weichselbaum RW, Bishop DK.

Nat Commun. 2019 Sep 27;10(1):4410. doi: 10.1038/s41467-019-12297-0.

2.

Tumor-reprogrammed resident T cells resist radiation to control tumors.

Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR.

Nat Commun. 2019 Sep 2;10(1):3959. doi: 10.1038/s41467-019-11906-2.

3.

STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer.

Gutiontov SI, Weichselbaum RR.

Cancer Res. 2019 Aug 1;79(15):3815-3817. doi: 10.1158/0008-5472.CAN-19-1700.

PMID:
31371279
4.

Integration of radiotherapy and immunotherapy for treatment of oligometastases.

Pitroda SP, Chmura SJ, Weichselbaum RR.

Lancet Oncol. 2019 Aug;20(8):e434-e442. doi: 10.1016/S1470-2045(19)30157-3. Epub 2019 Jul 29. Review.

PMID:
31364595
5.

Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer.

Foster CC, Pitroda SP, Weichselbaum RR.

J Thorac Oncol. 2019 Sep;14(9):1510-1512. doi: 10.1016/j.jtho.2019.05.025. Epub 2019 Jul 2. No abstract available.

PMID:
31272814
6.

Integrated molecular and clinical staging defines the spectrum of metastatic cancer.

Pitroda SP, Weichselbaum RR.

Nat Rev Clin Oncol. 2019 Sep;16(9):581-588. doi: 10.1038/s41571-019-0220-6. Review.

PMID:
31092903
7.

Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer.

Chan C, Guo N, Duan X, Han W, Xue L, Bryan D, Wightman SC, Khodarev NN, Weichselbaum RR, Lin W.

Biomaterials. 2019 Jul;210:94-104. doi: 10.1016/j.biomaterials.2019.04.028. Epub 2019 Apr 28.

PMID:
31060867
8.

Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy.

Lu K, He C, Guo N, Chan C, Ni K, Lan G, Tang H, Pelizzari C, Fu YX, Spiotto MT, Weichselbaum RR, Lin W.

Nat Biomed Eng. 2018 Aug;2(8):600-610. doi: 10.1038/s41551-018-0203-4. Epub 2018 Mar 26.

PMID:
31015630
9.

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors.

Duan X, Chan C, Han W, Guo N, Weichselbaum RR, Lin W.

Nat Commun. 2019 Apr 23;10(1):1899. doi: 10.1038/s41467-019-09221-x.

10.

Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.

Voce DJ, Bernal GM, Wu L, Crawley CD, Zhang W, Mansour NM, Cahill KE, Szymura SJ, Uppal A, Raleigh DR, Spretz R, Nunez L, Larsen G, Khodarev NN, Weichselbaum RR, Yamini B.

Cancer Res. 2019 May 15;79(10):2536-2548. doi: 10.1158/0008-5472.CAN-18-2170. Epub 2019 Apr 2.

PMID:
30940658
11.

Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features.

Foster CC, Pitroda SP, Weichselbaum RR.

J Clin Oncol. 2019 May 20;37(15):1270-1276. doi: 10.1200/JCO.18.02021. Epub 2019 Apr 2. No abstract available.

PMID:
30939093
12.

Author Correction: Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells.

Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wang J, Dougherty U, Bissonnette MB, Shen B, Weichselbaum RR, Xu MM, He C.

Nature. 2019 Apr;568(7751):E3. doi: 10.1038/s41586-019-1046-1.

PMID:
30911170
13.

Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.

Khan MK, Nasti TH, Buchwald ZS, Weichselbaum RR, Kron SJ.

Cancer J. 2019 Mar/Apr;25(2):106-115. doi: 10.1097/PPO.0000000000000369.

PMID:
30896532
14.

Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells.

Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wang J, Dougherty U, Bissonnette MB, Shen B, Weichselbaum RR, Xu MM, He C.

Nature. 2019 Feb;566(7743):270-274. doi: 10.1038/s41586-019-0916-x. Epub 2019 Feb 6. Erratum in: Nature. 2019 Apr;568(7751):E3.

15.

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.

Foster CC, Sher DJ, Rusthoven CG, Verma V, Spiotto MT, Weichselbaum RR, Koshy M.

Radiat Oncol. 2019 Jan 28;14(1):18. doi: 10.1186/s13014-019-1222-3.

16.

Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.

Huang L, David O, Cabay RJ, Valyi-Nagy K, Macias V, Zhong R, Wenig B, Feldman L, Weichselbaum R, Spiotto MT.

Clin Cancer Res. 2019 Mar 15;25(6):1795-1808. doi: 10.1158/1078-0432.CCR-18-1884. Epub 2018 Dec 20.

PMID:
30573692
17.

DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs.

Oshima G, Poli EC, Bolt MJ, Chlenski A, Forde M, Jutzy JMS, Biyani N, Posner MC, Pitroda SP, Weichselbaum RR, Khodarev NN.

Cancer Res. 2019 Feb 1;79(3):650-662. doi: 10.1158/0008-5472.CAN-18-0692. Epub 2018 Dec 11.

PMID:
30538122
18.

Oligometastatic prostate cancer: Reality or figment of imagination?

Foster CC, Weichselbaum RR, Pitroda SP.

Cancer. 2019 Feb 1;125(3):340-352. doi: 10.1002/cncr.31860. Epub 2018 Dec 6. Review.

19.

STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability.

Ranoa DRE, Widau RC, Mallon S, Parekh AD, Nicolae CM, Huang X, Bolt MJ, Arina A, Parry R, Kron SJ, Moldovan GL, Khodarev NN, Weichselbaum RR.

Cancer Res. 2019 Apr 1;79(7):1465-1479. doi: 10.1158/0008-5472.CAN-18-1972. Epub 2018 Nov 27.

PMID:
30482772
20.

Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.

Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR.

Nat Commun. 2018 Nov 13;9(1):4827. doi: 10.1038/s41467-018-07303-w.

21.

Oxygen-Guided Radiation Therapy.

Epel B, Maggio MC, Barth ED, Miller RC, Pelizzari CA, Krzykawska-Serda M, Sundramoorthy SV, Aydogan B, Weichselbaum RR, Tormyshev VM, Halpern HJ.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):977-984. doi: 10.1016/j.ijrobp.2018.10.041. Epub 2018 Nov 8.

PMID:
30414912
22.

The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment.

Weichselbaum RR.

J Clin Oncol. 2018 Sep 27:JCO1800847. doi: 10.1200/JCO.18.00847. [Epub ahead of print]

PMID:
30260759
23.

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.

Romero-Calvo I, Weber CR, Ray M, Brown M, Kirby K, Nandi RK, Long TM, Sparrow SM, Ugolkov A, Qiang W, Zhang Y, Brunetti T, Kindler H, Segal JP, Rzhetsky A, Mazar AP, Buschmann MM, Weichselbaum R, Roggin K, White KP.

Mol Cancer Res. 2019 Jan;17(1):70-83. doi: 10.1158/1541-7786.MCR-18-0531. Epub 2018 Aug 31.

PMID:
30171177
24.

Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy.

Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, Zhang Y, Yu X, Xu M, Mauceri H, Arina A, Weichselbaum RR, Fu YX.

Immunity. 2018 Sep 18;49(3):490-503.e4. doi: 10.1016/j.immuni.2018.07.008. Epub 2018 Aug 28.

25.

A Critical Role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis.

Cai Y, Xue F, Quan C, Qu M, Liu N, Zhang Y, Fleming C, Hu X, Zhang HG, Weichselbaum R, Fu YX, Tieri D, Rouchka EC, Zheng J, Yan J.

J Invest Dermatol. 2019 Jan;139(1):146-156. doi: 10.1016/j.jid.2018.07.025. Epub 2018 Aug 16.

PMID:
30120937
26.

BCL3 expression promotes resistance to alkylating chemotherapy in gliomas.

Wu L, Bernal GM, Cahill KE, Pytel P, Fitzpatrick CA, Mashek H, Weichselbaum RR, Yamini B.

Sci Transl Med. 2018 Jul 4;10(448). pii: eaar2238. doi: 10.1126/scitranslmed.aar2238.

27.

Nanoscale Metal-Organic Frameworks for Therapeutic, Imaging, and Sensing Applications.

Lu K, Aung T, Guo N, Weichselbaum R, Lin W.

Adv Mater. 2018 Sep;30(37):e1707634. doi: 10.1002/adma.201707634. Epub 2018 Jul 4. Review.

28.

Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy.

Ni K, Lan G, Chan C, Quigley B, Lu K, Aung T, Guo N, La Riviere P, Weichselbaum RR, Lin W.

Nat Commun. 2018 Jun 15;9(1):2351. doi: 10.1038/s41467-018-04703-w.

29.

Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.

Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR.

Nat Commun. 2018 May 4;9(1):1793. doi: 10.1038/s41467-018-04278-6. Erratum in: Nat Commun. 2018 Nov 13;9(1):4827.

30.

ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response.

Murley JS, Arbiser JL, Weichselbaum RR, Grdina DJ.

Free Radic Biol Med. 2018 Aug 1;123:39-52. doi: 10.1016/j.freeradbiomed.2018.04.547. Epub 2018 Apr 13.

PMID:
29660403
31.

Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.

Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic JJ, Milano MT, Chmura SJ, Salama JK.

PLoS One. 2018 Apr 12;13(4):e0195149. doi: 10.1371/journal.pone.0195149. eCollection 2018.

32.

JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers.

Pitroda SP, Stack ME, Liu GF, Song SS, Chen L, Liang H, Parekh AD, Huang X, Roach P, Posner MC, Weichselbaum RR, Khodarev NN.

Mol Cancer Ther. 2018 Apr;17(4):732-739. doi: 10.1158/1535-7163.MCT-17-0667. Epub 2018 Feb 21.

33.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

34.

Host STING-dependent MDSC mobilization drives extrinsic radiation resistance.

Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, Zheng W, Mauceri H, Mack M, Xu M, Fu YX, Weichselbaum RR.

Nat Commun. 2017 Nov 23;8(1):1736. doi: 10.1038/s41467-017-01566-5.

35.

Retuning the Radio in Radiobiology.

Chmura SJ, Connell PP, Weichselbaum RR.

J Natl Cancer Inst. 2018 Apr 1;110(4):325-326. doi: 10.1093/jnci/djx234. No abstract available.

PMID:
29126281
36.

A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.

Patel P, Oh AL, Koshy M, Sweiss K, Saraf SL, Quigley JG, Khan I, Mahmud N, Hacker E, Ozer H, Peace DJ, Weichselbaum RR, Aydogan B, Rondelli D.

Leuk Lymphoma. 2018 Jul;59(7):1666-1671. doi: 10.1080/10428194.2017.1390231. Epub 2017 Oct 25.

PMID:
29065747
37.

HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation.

Efimova EV, Ricco N, Labay E, Mauceri HJ, Flor AC, Ramamurthy A, Sutton HG, Weichselbaum RR, Kron SJ.

Mol Cancer Ther. 2018 Feb;17(2):407-418. doi: 10.1158/1535-7163.MCT-17-0288. Epub 2017 Oct 13.

38.

Survival outcomes for postoperative chemoradiation in intermediate-risk oral tongue cancers.

Spiotto MT, Jefferson GD, Wenig B, Markiewicz MR, Weichselbaum RR, Koshy M.

Head Neck. 2017 Dec;39(12):2537-2548. doi: 10.1002/hed.24932. Epub 2017 Sep 27.

PMID:
28960621
39.

Association between hospital volume and receipt of treatment and survival in patients with glioblastoma.

Koshy M, Sher DJ, Spiotto M, Husain Z, Engelhard H, Slavin K, Nicholas MK, Weichselbaum RR, Rusthoven C.

J Neurooncol. 2017 Dec;135(3):529-534. doi: 10.1007/s11060-017-2598-2. Epub 2017 Aug 23.

PMID:
28836140
40.

TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response.

Murley JS, Miller RC, Weichselbaum RR, Grdina DJ.

Radiat Res. 2017 Nov;188(5):579-590. doi: 10.1667/RR14831.1. Epub 2017 Aug 16.

41.

Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling.

Xu MM, Pu Y, Han D, Shi Y, Cao X, Liang H, Chen X, Li XD, Deng L, Chen ZJ, Weichselbaum RR, Fu YX.

Immunity. 2017 Aug 15;47(2):363-373.e5. doi: 10.1016/j.immuni.2017.07.016. Epub 2017 Aug 8.

42.

Rhythmic radiotherapy beats down TGF-β.

Chmura SJ, Weichselbaum RR.

Cell Cycle. 2017 Aug 3;16(15):1391. doi: 10.1080/15384101.2017.1337970. Epub 2017 Jul 19. No abstract available.

43.

Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation.

Zhang Y, Kim TJ, Wroblewska JA, Tesic V, Upadhyay V, Weichselbaum RR, Tumanov AV, Tang H, Guo X, Tang H, Fu YX.

Cell Mol Immunol. 2018 Jul;15(7):697-709. doi: 10.1038/cmi.2017.25. Epub 2017 Jun 5.

44.

In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases.

Oshima G, Guo N, He C, Stack ME, Poon C, Uppal A, Wightman SC, Parekh A, Skowron KB, Posner MC, Lin W, Khodarev NN, Weichselbaum RR.

Mol Ther. 2017 Jul 5;25(7):1588-1595. doi: 10.1016/j.ymthe.2017.04.005. Epub 2017 Apr 28.

45.

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T.

Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26.

46.

Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis.

Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M.

JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):691-699. doi: 10.1001/jamaoto.2017.0012.

47.

Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system.

Shukla V, Dalela M, Vij M, Weichselbaum R, Kharbanda S, Ganguli M, Kufe D, Singh H.

Nanomedicine. 2017 Jul;13(5):1833-1839. doi: 10.1016/j.nano.2017.03.004. Epub 2017 Mar 23.

48.

Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.

Pitroda SP, Bao R, Andrade J, Weichselbaum RR, Connell PP.

Clin Cancer Res. 2017 Aug 1;23(15):4493-4500. doi: 10.1158/1078-0432.CCR-16-2845. Epub 2017 Mar 24.

49.

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, Chen Z, Chen W, Liu X, Salomon AR, Liu H, Weichselbaum RR, Yu J, Peter ME.

Cell Rep. 2017 Mar 7;18(10):2373-2386. doi: 10.1016/j.celrep.2017.02.037.

50.

Radiotherapy and immunotherapy: a beneficial liaison?

Weichselbaum RR, Liang H, Deng L, Fu YX.

Nat Rev Clin Oncol. 2017 Jun;14(6):365-379. doi: 10.1038/nrclinonc.2016.211. Epub 2017 Jan 17. Review.

PMID:
28094262

Supplemental Content

Loading ...
Support Center